ArticlePharmacoEconomics - open2022

Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia.

Fabio Gil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.